We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NOMA:NASDAQNOMADAR Corp. Analysis

Data as of 2026-07-17 - not real-time

$3.06

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Nomadar Corp. is trading well below its 20‑day and 50‑day simple moving averages, with the 200‑day SMA still markedly higher, underscoring a sustained bearish bias. The RSI sits in the low‑40s, indicating neither oversold nor overbought conditions, while a negative MACD line and histogram reinforce downside momentum. Volatility is extreme, approaching 100% over the past 30 days, and the stock has endured a 75% max drawdown, which amplifies the risk of further price erosion.
Fundamentally, the company posts a healthy gross margin but an operating loss, negative earnings per share, and a negative operating cash flow, suggesting that profitability remains elusive. The balance sheet is strained, with total debt more than double cash on hand and a debt‑to‑equity ratio near 31, while valuation multiples are lofty—price‑to‑book above four and price‑to‑sales above 45—pointing to an overvalued equity price relative to its financial footing.
Given the confluence of bearish technical signals, high volatility, weak cash generation, and an inflated valuation, the outlook is cautious. Investors should be wary of the thin liquidity and the sector’s sensitivity to discretionary spending, especially in a leisure‑focused consumer cyclical environment.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • price below key moving averages and negative MACD
  • extreme short‑term volatility and recent 75% drawdown
  • weak operating cash flow and high debt load

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • potential upside from brand licensing and stadium assets
  • still elevated valuation multiples despite earnings deficits
  • moderate sector exposure that could improve if consumer spending recovers

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • ongoing operating losses and negative ROE
  • high leverage that may limit strategic investments
  • uncertain path to profitability despite strong gross margins

Key Metrics & Analysis

Financial Health

Revenue Growth116.00%
ROE-80.79%
ROA-20.90%
Debt/Equity30.92
P/B Ratio4.4
Op. Cash Flow$-1165777
Free Cash Flow$46.2K

Technical Analysis

TrendBearish
RSI42.9
Support$2.87
Resistance$4.45
MA 20$3.43
MA 50$3.44
MA 200$4.76
MACDBearish
VolumeStable
Fear & Greed Index88.07

Valuation

GradeOvervalued
TypeBlend

Risk Assessment

Beta-0.11
Volatility99.54%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.